company background image

GlaxoSmithKlineECASE:BIOC Stock Report

Market Cap







15 Oct, 2021


Company Financials
BIOC fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health4/6

BIOC Overview

GlaxoSmithKline S.A.E. operates as a research-based pharmaceutical and healthcare company.


Became profitable this year

Risk Analysis

High level of non-cash earnings

GlaxoSmithKlineE Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GlaxoSmithKlineE
Historical stock prices
Current Share Priceج.م26.41
52 Week Highج.م14.75
52 Week Lowج.م44.90
1 Month Change-12.87%
3 Month Change-24.39%
1 Year Change55.90%
3 Year Changen/a
5 Year Change136.65%
Change since IPO183.37%

Recent News & Updates

Shareholder Returns

BIOCEG PharmaceuticalsEG Market

Return vs Industry: BIOC exceeded the EG Pharmaceuticals industry which returned 2.2% over the past year.

Return vs Market: BIOC exceeded the EG Market which returned 8.2% over the past year.

Price Volatility

Is BIOC's price volatile compared to industry and market?
BIOC volatility
BIOC Beta1.1
Industry Beta0.87
Market Beta1

Stable Share Price: BIOC is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: BIOC's weekly volatility (7%) has been stable over the past year.

About the Company

1981n/aAmr Mamdouh Majid

GlaxoSmithKline S.A.E. operates as a research-based pharmaceutical and healthcare company. It offers a range of prescription medicines, vaccines, and consumer healthcare products. The company was founded in 1981 and is based in Cairo, Egypt.

GlaxoSmithKlineE Fundamentals Summary

How do GlaxoSmithKlineE's earnings and revenue compare to its market cap?
BIOC fundamental statistics
Market Capج.م2.21b
Earnings (TTM)ج.م176.98m
Revenue (TTM)ج.م1.93b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIOC income statement (TTM)
Cost of Revenueج.م1.04b
Gross Profitج.م892.03m

Last Reported Earnings

Sep 30, 2020

Next Earnings Date


Earnings per share (EPS)2.12
Gross Margin46.22%
Net Profit Margin9.17%
Debt/Equity Ratio19.3%

How did BIOC perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is GlaxoSmithKlineE undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: BIOC (EGP26.41) is trading above our estimate of fair value (EGP6.94)

Significantly Below Fair Value: BIOC is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: BIOC is poor value based on its PE Ratio (12.5x) compared to the EG Pharmaceuticals industry average (5.5x).

PE vs Market: BIOC is poor value based on its PE Ratio (12.5x) compared to the EG market (12.3x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIOC's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BIOC is overvalued based on its PB Ratio (1.7x) compared to the EG Pharmaceuticals industry average (1.3x).

Future Growth

How is GlaxoSmithKlineE forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlaxoSmithKlineE has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has GlaxoSmithKlineE performed over the past 5 years?


Last years revenue growth

Earnings and Revenue History

Quality Earnings: BIOC has a high level of non-cash earnings.

Growing Profit Margin: BIOC became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: BIOC has become profitable over the past 5 years.

Accelerating Growth: BIOC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BIOC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).

Return on Equity

High ROE: BIOC's Return on Equity (13.8%) is considered low.

Financial Health

How is GlaxoSmithKlineE's financial position?

Financial Position Analysis

Short Term Liabilities: BIOC's short term assets (EGP1.4B) exceed its short term liabilities (EGP875.1M).

Long Term Liabilities: BIOC has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: BIOC's debt to equity ratio (19.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if BIOC's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: BIOC's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: BIOC's interest payments on its debt are well covered by EBIT (3.9x coverage).

Balance Sheet


What is GlaxoSmithKlineE current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: BIOC's dividend (1.89%) isn’t notable compared to the bottom 25% of dividend payers in the EG market (2.69%).

High Dividend: BIOC's dividend (1.89%) is low compared to the top 25% of dividend payers in the EG market (7.43%).

Stability and Growth of Payments

Stable Dividend: BIOC is not paying a notable dividend for the EG market, therefore no need to check if payments are stable.

Growing Dividend: BIOC is not paying a notable dividend for the EG market, therefore no need to check if payments are increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIOC's dividend in 3 years as they are not forecast to pay a notable one for the EG market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Amr Mamdouh Majid

no data


Dr. Amr Mamdouh Abdel Majid serves as Chairman, Managing Director and Executive Director of GlaxoSmithKline S.A.E.

Leadership Team

Experienced Management: BIOC's management team is considered experienced (2.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

GlaxoSmithKline S.A.E's employee growth, exchange listings and data sources

Key Information


  • GlaxoSmithKline S.A.E
  • Boomerang Building
  • No 46, Block J First Section City Centre
  • Cairo
  • Egypt


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/15 14:31
End of Day Share Price2021/10/14 00:00
Annual Earnings2019/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.